

### **REMARKS**

Claims 21-44 are pending in the application. Claims 23 and 30 are hereby canceled. Claims 21, 22, 28, and 29 are amended. Support for these amendments can be found in previously filed claims 23 and 30. The specification is amended to correct typographical errors.

Applicants believe no new matter is added by the foregoing amendments.

#### **I. Amendments to the Specification**

The Examiner noted that the specification contained typographical errors in the paragraph beginning on page 3, line 17. Applicants have amended the specification to correct these errors.

#### **II. Rejection of Claims 21, 22, 24-29, and 31-34 under 35 U.S.C. 112, First Paragraph**

The Examiner rejected claims 21, 22, 24-29, and 31-34 under 35 U.S.C. 112, first paragraph. Specifically the Examiner found that the specification did not enable one skilled in the art to make and use a polypeptide having at least 90% or 95% identity to the polypeptide of SEQ ID NO: 12 or 14, or an extracellular domain having 90% or 95% identity to the extracellular domain of SEQ ID NO: 12 or 14. To expedite prosecution, Applicants have amended claims 21, 22, 28, and 29 to recite that the polypeptide associates with a DAP12 polypeptide having an amino acid sequence of SEQ ID NO: 2 or 6.

In view of the foregoing, Applicants submit that amended claims 21, 22, 28, and 29 are now free from this rejection, as are dependent claims 24-29 and 31-34. Withdrawal of this rejection is respectfully requested.

### **Conclusion**

Applicants' current response is believed to be a complete reply to all the outstanding issues of the latest Office action. Further, the present response is a bona fide effort to place the application in condition for allowance or in better form for appeal. Accordingly, Applicants respectfully request reconsideration and passage of the amended claims to allowance at the earliest possible convenience.

Applicant believes that no additional fees are due with this communication. Should this not be the case, the Commissioner is hereby authorized to debit any charges or refund any overpayments to DNAX Deposit Account No. 04-1239.

If the Examiner believes that a telephonic conference would aid the prosecution of this case in any way, please call the undersigned.

Respectfully submitted,

Date: 5 September 2007

By: /Sheela Mohan-Peterson/  
Sheela Mohan-Peterson, Reg. No. 41,201  
Attorney for Applicants

Customer No. 028008  
DNAX Research, Inc.  
901 California Avenue  
Palo Alto, CA 94304-1104  
Telephone (Switchboard): (650) 496-6400  
Telephone No. (Direct): (650) 496-1244  
Facsimile No.: (650) 496-1200